This company has been marked as potentially delisted and may not be actively trading. Orphazyme A/S (ORPH) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period How Four Sigmatic Made Mushrooms A Multi-Billion Dollar CategoryNovember 11, 2024 | forbes.comWeight loss care is leading IPO-hopeful Omada Health's latest growth surge as Ozempic boom continuesOctober 30, 2024 | businessinsider.comIncyte’s Strong Financial Performance and Promising Pipeline Lead to Buy RatingOctober 30, 2024 | markets.businessinsider.comOzempic could help reduce Alzheimer’s risk for some, study suggests: ‘Shifting the paradigm’October 26, 2024 | msn.comAquestive Therapeutics’ Favorable OAS Study Boosts Anaphylm’s Prospects with Raised Price Target and Buy RatingOctober 25, 2024 | markets.businessinsider.comNovo’s Ozempic Linked to Reduced Alzheimer’s DiagnosesOctober 24, 2024 | msn.comHow Europe's Biggest Buyout Deal Descended Into a Bruising BrawlOctober 24, 2024 | bloomberg.comNasdaq Welcomes Strategic Partners A/S to Nasdaq Copenhagen Main MarketOctober 24, 2024 | finanznachrichten.deUK regulator approves second Alzheimer's drug in months but government won't pay for itOctober 23, 2024 | abcnews.go.comFDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 YearsOctober 23, 2024 | benzinga.comArtiphon’s new Orba instrument can sample sounds liveOctober 22, 2024 | techcrunch.comInjectable drug to ease advanced Parkinson's disease symptoms approved by FDAOctober 17, 2024 | msn.comUS FDA expands approval for Avadel's sleep disorder drugOctober 17, 2024 | msn.comFDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And AdolescentsOctober 12, 2024 | markets.businessinsider.comKathy Bates Sets the Record Straight on Her Ozempic Use After Losing 100 Lbs.: 'There’s Been a Lot of Talk' (Exclusive)October 11, 2024 | msn.comPfizer’s Hympavzi Wins FDA Approval to Treat HemophiliaOctober 11, 2024 | msn.comPfizer’s Hympavzi Approved for Treatment of Certain Types of HemophiliaOctober 11, 2024 | msn.comAlkermes’s Promising Orexin Drug Development Positions Company for Market LeadershipOctober 10, 2024 | markets.businessinsider.comPfizer’s Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta SetbackSeptember 27, 2024 | markets.businessinsider.comFDA approves a novel drug for schizophrenia, a potential ‘game changer’September 27, 2024 | washingtonpost.comF.D.A. Approves the First New Schizophrenia Drug in DecadesSeptember 27, 2024 | nytimes.comPfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta PullSeptember 25, 2024 | msn.comFDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C -- UpdateSeptember 21, 2024 | marketwatch.comWhy Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'September 12, 2024 | benzinga.comAscendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.September 12, 2024 | marketwatch.comLifera Omics Appoints Prof. Fowzan Alkuraya, a Renowned Genomics Expert as Chief Medical and Genomic OfficerSeptember 10, 2024 | markets.businessinsider.comUK drug regulator approves Alzheimer's drug but government likely won't pay for itAugust 23, 2024 | msn.comNew Alzheimer's drug deemed too costly for UK's state-run health serviceAugust 22, 2024 | msn.comCheap copycat Ozempic sounds too good to be true. It is, a scientist found.August 18, 2024 | businessinsider.comIncyte’s New Drug Approval Overcast by Market Limitations and Looming Patent ExpirationsAugust 15, 2024 | markets.businessinsider.comAscendis Pharma Shares Climb on U.S. FDA Approval for Hypoparathyroidism Treatment YorvipathAugust 12, 2024 | marketwatch.comPfizer's Respiratory Syncytial Virus Vaccine Data Shows Promise In Subgroup Of Younger Immunocompromised PatientsAugust 12, 2024 | msn.comAscendis Pharma’s stock rises after FDA approval for first and only treatment for rare diseaseAugust 12, 2024 | msn.comA pill that reverses Alzheimer’s disease? This medical breakthrough shows promise.August 9, 2024 | msn.comAlzheimer's Breakthrough as Parkinson's Drug Surprise Teases New TreatmentAugust 8, 2024 | msn.comBreakthrough molecule reverses Alzheimer's symptomsAugust 8, 2024 | msn.comZevra wins FDA panel backing for previously rejected arimoclomolAugust 6, 2024 | finance.yahoo.comFDA Panel to Consider Arimoclomol for Rare Genetic DisorderAugust 2, 2024 | msn.comNovo's older obesity drug shows biological effect on Alzheimer's patients in small trialJuly 31, 2024 | reuters.comAlzheimer’s Blood Test Outperforms Standard Diagnostics in New StudyJuly 29, 2024 | msn.comBlood tests for Alzheimer's may be coming to your doctor's office. Here's what to knowJuly 29, 2024 | msn.comHow a new technology might accelerate Alzheimer's testing, treatment for millionsJuly 28, 2024 | msn.comSun Pharma's Leqselvi 8 Mg Tab Gets FDA Approval For Adults With Severe Alopecia AreataJuly 26, 2024 | markets.businessinsider.comNasal spray clears proteins linked to Alzheimer's, study findsJuly 26, 2024 | msn.comAbbott Laboratories's Options Frenzy: What You Need to KnowJuly 26, 2024 | benzinga.comOligodendrocytes identified as key amyloid β producers in Alzheimer's diseaseJuly 25, 2024 | msn.comPfizer’s Treatment for Bleeding Disorder Meets Goal in TrialJuly 25, 2024 | bloomberg.comBreakthrough nasal spray could clear away Alzheimer's-causing proteins in the brainJuly 22, 2024 | yahoo.comWe're Closer Than Ever To Beating Alzheimer's. Price Controls Could Change That.July 22, 2024 | forbes.comFrom Dr. Oz to heart valves: A tiny device charted a contentious path through the FDAJuly 21, 2024 | chicago.suntimes.com Remove Ads Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address ORPH Media Mentions By Week ORPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPH News Sentiment▼-0.020.53▲Average Medical News Sentiment ORPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPH Articles This Week▼02▲ORPH Articles Average Week Remove Ads Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Seres Therapeutics News Today Enanta Pharmaceuticals News Today Eupraxia Pharmaceuticals News Today Regulus Therapeutics News Today Zentalis Pharmaceuticals News Today Coya Therapeutics News Today Virios Therapeutics News Today Procaps Group News Today Genelux News Today BioHarvest Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPH) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Orphazyme A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORPH Stock Free ORPH Stock Alerts